A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer
Phase 1
Completed
- Conditions
- Esophageal Cancer
- Interventions
- Drug: C11-Choline
- Registration Number
- NCT01051479
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
The purpose of this study is to evaluate the investigators ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Newly diagnosed or recurrent patients with locally advanced esophageal cancer with either squamous or adenocarcinoma histology.
- Ability to tolerate PET imaging
- Prior malignancy is allowed, but the expectation of survival must be that beyond that expected for patients with locally advanced esophageal cancer.
Exclusion Criteria
- Pregnant or lactating females are not eligible for this pilot study.
- Patients having received chemotherapy in the 3 months prior to registration for any reason
- Patients with metastatic disease requiring chemoradiation for palliation are not allowed.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description C11-Choline C11-Choline -
- Primary Outcome Measures
Name Time Method To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy). 2 years
- Secondary Outcome Measures
Name Time Method Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis. 2 years
Trial Locations
- Locations (1)
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States